know jakafikey updat ahead
updat jakafi number ahead earn base script
growth estim growth revenu also updat
model includ sever pipelin asset highlight recent data
expect next month exhibit topic ruxolitinib atop
dermat risk-unadjust peak po itacitinib steroid-refractori
cholangiocarcinoma bladder cancer risk-unadjust peak po
inhibitor b-cell malign risk-unadjust peak
adjust sever pipelin combo could defend jakafi competit
adjust increas pt detail exhibit insid
updat jakafi sale base script growth vs
histor growth rate
respect histor took price hike year
expect sale growth jakafi us sale exhibit base
see opportun delay reduc need system therapi atop
dermat topic ruxolitinib data show efficaci vs placebo
highest bid arm superior efficaci vs activ control exhibit
line vehicl treatment data present eadv septemb
regulatori discuss underway
high select itacitinib rational develop steroid-
naiv set jakafi develop steroid-refractori patient poc data
itacitinib plu steroid agvhd show orr first-lin
patient exhibit initi global trial itacitinib newli diagnos
agvhd data anticip
inhibitor shown low select
develop cholangiocarcinoma chemo bat
bladder cancer exhibit bladder see potenti use low
patient bar keytruda inhibitor show
signal fl mzl mcl exhibit
model revenu includ mileston non-
dilut ep sever option mpn combin top
jakafi could solidifi franchis potenti competit earli data
avail sever combin remain perform
rate adjust pt
biopharma compani
focus small molecul oncolog
jakafi
analyst certif import disclosur see disclosur
develop epacadostat discontinu
regulatori approv launch baricitinib
inhibitor signific potenti myelofibrosi mf
polycythemia vera pv potenti indic
clinic investig partner candid baricitinib oral
therapi ra face signific us regulatori delay may
drive revenu upsid eventu deep
driven take-over specul lead valuat premium
fair market valuat view
snda submiss jakafi acut gvhd base
gvhd result
potenti fda approv jakafi agvhd
greater expect advanc pipelin asset
pipelin asset fail differenti offer strateg advantag
collabor
price target per share base dcf valuat methodolog employ wacc termin growth rate
view appropri compani commerci asset clinical-stag pipelin estim jakafi sale could peak
us includ peak royalti ex-u sale see iclusig olumi smaller contributor revenu
key known downsid risk price target clinic develop risk regulatori risk pipelin addit risk come
build commerci infrastructur indic higher anticip competit drug develop
upsid risk includ acquisit signific premium better expect clinic data drug pipelin
exhibit dcf valuat
discount analysisoppenheim co except per-shar data revenu chang work work capit thru upequ valu growth valu valu growth rateequ valu per sharetermin valu growth rate
ido failur highlight sever pipelin asset investor day
led us updat sale model
 raupdat baricitinib resubmiss treatment rheumatoid steriod-refractori acut gvhd rapotenti approv ra psoriat arthritislli initi pivot data ruxolitinibsnda data present atop dermat workshop eadv sept ruxolitinibdata present steroid-refractori acut fgfr file nda fgfr full data bladder potenti subsequ registr citadel trial fl mzl mcl steroid-na acut gvhd compani report oppenheim co inc probabl prob -unadjust product jakavi ex-u iclusig growth olumi eu olumi topic itacitinib rest sale probabl prob -adjust product jakavi ex-u prob -adjust prob -adjust topic prob -adjust itacitinib prob -adjust prob -adjust prob -adjust rest probabl adjust perform
exhibit quarterli us jakafi sale indic growth vs
exhibit jakafi growth sale typic greater growth
estim growth sale vs sale
see topic ruxolotinib well-differenti asset patient atop
dermat potenti sever indic focu atop dermat
sinc earliest market opportun plan
exhibit sever cytokin play role atop dermat drive
diseas jak/stat pathway target
skin lesion atop dermat predomin character increas
express cytokin epitheli cytokin ruxolitinib
potenti disrupt jak/stat depend signal pathway sever
treatment option exist topic ruxolitinib could differenti delay
reduc need system therapi trial patient iga
baselin score skin involv topic ruxolitinib
compar vehicl cream triamcinolon cream activ compar topic
ruxolitinib show superior placebo concentr
bid bid arm outperform activ control
triamcinolon cream esai score iga respond data
present later year potenti atop dermat workshop eadv
exhibit data show efficaci topic ruxolitinib beat
activ control triamcinolon cream highest dose
model use moder sever patient set launch
topic ruxolitinib compet phototherapi system therapi
dupilumab/or corticosteroids/ciclosporin cream
protop pimecrolimu elidel model price base otezla
remicad psoriasi medic gross-to-net adjust
also assum patient cycl treatment cream use
four month per year model peak risk-unadjust sale
us row risk adjust
itacitinib first treatment gvhd
itacitinib select inhibitor due select
develop first-lin treatment chronic acut gvhd recal jakafi
develop steroid-refractori gvhd reach program
report posit data single-arm studi data data
acut gvhd compar bat expect poc trial
itacitinib plu steroid acut gvhd includ first- second-lin
patient grade iib-ivd gvhd show orr first-lin patient
patient respons similar dose
group initi global trial newli diagnos agvhd gravitas-
data anticip potenti file data posit
exhibit itacitinib show respons rate gvhd poc studi
sever drug use gvhd off-label itacitinib approv could greatli
chang treatment landscap steroid-nav gvhd
approv newer therapi model peak market share launch
orphan drug price averag three month treatment
durat risk-unadjust sale reach us row
risk adjust base posit poc data patient
fgfr inhibitor
fibrorblast growth factor receptor fgfr oncogen driver
fgfr inhibitor exist hope differenti
high select fgfr lower select off-target receptor
exhibit compar fgfr inhibitor select
form lower select
develop inhibitor cholangiocarcinoma bladder cancer
mpf cholangiocarcinoma rare cancer bile duct epitheli cell
treat chemotherapi low respons rate low os
month single-arm poc trial patient advanc
metastat unresect cholangiocarcinoma plan file nda
prepar confirmatori trial vs chemotherapi
exhibit cholangiocarcinoma manag safeti
best orr
also develop bladder cancer
metastat surgic unresect urotheli carcinoma fgfr
mutations/alter week week manag show
manag safeti orr full data expect may
exhibit bladder manag safeti best orr
bladder seen recent approv checkpoint inhibitor warn
fda restrict use low patient ref base earli review
data monitor committe
nevertheless sever option exist bladder
exhibit nccn guidelin system therapi bladder cancer
see potenti use patient mutat
low express checkpoint inhibitor
use potenti half posit patient
efficacy/safeti superior approv checkpoint inhibitor
orr seem roughli line current trial vs keytruda
ae profil could play role administr iv vs small molecul
model class share mutat patient low
express half peak market share
assum one fgfr competitor model durat treatment
base patient treatment price line
estim risk-unadjust peak sale bladder cancer us
row risk adjust
exhibit keytruda efficaci cisplatin-inelig patient
exhibit keytruda safeti cisplatin-inelig patient
approv idealisib inhibitor success nhl
inhibitor inhibit one enzym part
dysregul list inhibitor approv clinic
develop idealisib copanlisib
small molecul inhibitor target delta isoform
select toward compar isoform peer
impact mani hallmark cancer
exhibit target pathway b-cell
exhibit differenti highest select
initi citadel clinic program evalu non-
hodgkin lymphoma nhl includ patient diffus larg b-cell lymphoma
dlbcl follicular lymphoma fl margin zone lymphoma mzl mantl
data show manag safeti efficaci fl mcl mzl
respons could allow short-term qd dose follow switch qw dose
manag long-term toler initi orr look promis fl mzl
mcl need follow patient
believ good bar could recent file inhibitor duvelisib
nda support clinic data phase duo studi phase
exhibit trial result b-cell
exhibit dynamo trial result duvelisib fl
model sale fl mcl mzl potenti launch
assum averag durat treatment six month first year
respond continu therapi addit six month year
assum wac price discount model risk un-
adjust sale us row risk adjust
thousand except per share
product royalti revenu olumi us eu row
jakafi essenti thrombocythemia et
jakafi gvhd
probabl success
probabl success
probabl success
probabl success
probabl success
mileston contract research
licens royalti
cost expens
good sold royalti jakafi
good sold amortizatin iclusig right eu
good sold small mol
good sold biolog
amort acquir product right
research develop
adjust research develop non-gaap
up-front consider collabor
share-bas compens
share-bas compens expens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
share-bas compens sg expens
incom loss oper
incom expens
interest incom expens net
loss debt repurchas
unreal gain long term invest
ep basic dilut
ep non-gaap basic dilut
share use comput ep basic
share use comput ep dilut
fulli dilut share out use valuat
